The Latest in Critical Care, 9/28/23 (Issue #15)
PulmCCM
SEPTEMBER 28, 2023
with Covid-19 randomized to 800 μg of inhaled budesonide twice daily had significantly fewer urgent care visits, and faster resolution of symptoms. In the STOIC trial (a phase 2, open-label, randomized trial), 146 outpatients in the U.K. Natural and vaccine-induced immunity are expected to be protective against severe illness.
95 
Let's personalize your content